Soleus Capital Management L.P. Has $80.71 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Soleus Capital Management L.P. raised its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 5.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,681,242 shares of the biopharmaceutical company’s stock after buying an additional 146,702 shares during the quarter. TG Therapeutics comprises approximately 5.1% of Soleus Capital Management L.P.’s holdings, making the stock its 3rd largest position. Soleus Capital Management L.P. owned about 1.72% of TG Therapeutics worth $80,705,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. grew its stake in TG Therapeutics by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company’s stock valued at $469,454,000 after acquiring an additional 209,190 shares in the last quarter. Clearbridge Investments LLC bought a new position in shares of TG Therapeutics during the 4th quarter valued at about $55,237,000. Northern Trust Corp increased its holdings in shares of TG Therapeutics by 8.6% in the fourth quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company’s stock worth $46,141,000 after purchasing an additional 120,785 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of TG Therapeutics by 7.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company’s stock worth $38,212,000 after purchasing an additional 84,904 shares during the last quarter. Finally, Invesco Ltd. lifted its position in shares of TG Therapeutics by 1.2% in the fourth quarter. Invesco Ltd. now owns 929,743 shares of the biopharmaceutical company’s stock worth $27,985,000 after buying an additional 10,989 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Trading Up 2.3%

Shares of NASDAQ TGTX opened at $34.36 on Monday. TG Therapeutics, Inc. has a 1-year low of $15.16 and a 1-year high of $46.48. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The business’s 50 day moving average is $38.59 and its two-hundred day moving average is $34.03. The stock has a market capitalization of $5.45 billion, a P/E ratio of -343.57 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.16). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $120.86 million during the quarter, compared to analysts’ expectations of $117.07 million. During the same quarter last year, the firm posted ($0.07) EPS. TG Therapeutics’s revenue for the quarter was up 90.4% compared to the same quarter last year. As a group, research analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on TGTX shares. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $40.80.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.